Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

The use of immediate postoperative intravesical chemotherapy (IVC) following transurethral resection of bladder tumor (TURBT) has been shown to reduce the rate of recurrence of nonmuscle invasive ...

Both chemotherapy and immunotherapy are effective cancer treatment ... The other method is Intravesical, in which immunotherapy is administered straight into the bladder. By leveraging the body ...

is being voluntarily withdrawn from the US market for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received platinum-containing chemotherapy and a ...

Non-muscle-invasive bladder cancer is labor intensive and costly to manage. Owing to long-term survival rates and life-long monitoring and treatment, it is the most expensive cancer to manage in ...

Female bladder cancer patients undergoing bladder-sparing therapies often experience minimal disruption to sexual health compared to those undergoing cystectomy. The study underscores the need for ...

Oct 18 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the ...

for adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either programmed death receptor-1 (PD-1) or programmed ...

The TROP2-directed antibody-drug conjugate failed to top chemotherapy at extending the lives of bladder cancer patients who had tried a PD-1/L1 therapy and chemo. Detailed data of that flop have ...